Rabies Vaccine(MRC-5 Cell)(Anhui Zhifei Longcom Biologic Pharmacy)

In the population aged 10-60 years: It was demonstrated that when the trial vaccine was administered with a 5-dose schedule, 14 days after the first dose, the immunogenicity of the 5-dose trial group was non-inferior to that of the control group (5 doses); It was demonstrated that when the trial vaccine was administered with a 4-dose schedule, 14 days after the first dose, the immunogenicity of the 4-dose trial group was non-inferior to that of the control group (5 doses); It was demonstrated that when the trial vaccine was administered with a 5-dose schedule or a 4-dose schedule, 14 days after the full vaccination, the antibody seroconversion rate reached 100%; The safety of vaccination with the trial vaccine was evaluated.